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Abstract
Background: Pain is often a dominant clinical feature of chronic pancreatitis but the frequency
and severity is highly variable between subjects. We hypothesized that genetic polymorphisms
contribute to variations in clinical pain patterns. Since genetic variations in the GTP cyclohydrolase
(GCH1) gene have been reported to protect some patients from pain, we investigated the effect
of the "pain protective haplotype" in well characterized patients with chronic pancreatitis (CP) or
recurrent acute pancreatitis (RAP) from the North American Pancreatitis Study 2 (NAPS2).
Results: Subjects in the NAPS2 study were asked to rank their pain in one of 5 categories
reflecting different levels of pain frequency and severity. All subjects were genotyped at rs8007267
and rs3783641 to determine the frequency of the GCH1 pain-protective haplotype. In Caucasian
subjects the frequency of the pain-protective GCH1 haplotype was no different in the control
group (n = 236), CP patients (n = 265), RAP patients (N = 131), or in CP patients subclassified by
pain category compared to previously reported haplotype frequencies in the general Caucasian
population.
Conclusion: The GCH1 pain-protective haplotype does not have a significant effect on pain
patterns or severity in RAP or CP. These results are important for helping to define the regulators
of visceral pain, and to distinguish different mechanisms of pain.
Introduction
Chronic pancreatitis (CP) is a chronic inflammatory dis-
order of the pancreas characterized by progressive destruc-
tion of the parenchyma, loss of exocrine and endocrine
function, and in many cases, severe abdominal pain [1,2].
The problem of pain in CP is complex and has been diffi-
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cult to study because of the multiple contributing etiolo-
gies, the variable frequency and severity of pain, and other
challenges that are common in the study of visceral pain
[3,4]. The commonly recognized etiologies and treat-
ments have been reviewed elsewhere [3]. However, the
possibility that a component of the variance in pancreatic
pain severity or chronicity is genetically determined has
not been explored.
Based on clinical experience in Zurich Switzerland,
Ammon et al describe two distinct patterns of pain in
patients with alcoholic CP (>90% males) as A Type (epi-
sodic pain with pain-free intervals) and B Type (continu-
ous pain with exacerbations) [5]. B-type pain was
considered the most severe, requiring significantly more
hospitalizations and surgical interventions for attempted
pain relief. These findings are consistent with pain in
other disorders where pain severity correlated with inter-
ference in daily functioning [6].
Tegeder et al. [7] reported that specific genetic variations
in the GTP cyclohydrolase (GCH1) gene were associated
with reduced severity of persistent leg pain in Caucasian
patients with chronic radicular disease who underwent
diskectomy, as well as with lower ratings of experimental
pain stimuli in normal young adults. GCH1 is the rate
limiting enzyme in the production of 6(R)-L-erythro-
5,6,7,8-tetrahydrobiopterin (BH4). BH4 is a key cofactor
in the synthesis of several pain neuromodulators includ-
ing catecholamines, serotonin and nitric oxide and is
important in the metabolism of phenylalanine [8]. BH4
appears to increase pain sensitivity by upregulation of
nitric oxide [7]. Therefore, changes in GCH1 activity
would alter BH4 levels and could thereby modulate pain
signaling. Tegeder et al. discovered an uncommon haplo-
type in the GCH1 gene (termed the pain-protective haplo-
type) found in about 15% of Caucasians' chromosomes
containing 5 single nucleotide polymorphisms (SNPs)
significantly associated with low pain, including
rs8007267G>A and rs3783641A>T [7,9]. Whether the
same "pain-protective haplotype" seen in this neuro-
pathic and experimental pain study alters pain severity or
frequency in visceral pain syndromes, including CP, is
unknown.
We tested the hypothesis that the "pain-protective haplo-
type" is protective for CP pain severity and chronicity.
Thus, patients with this haplotype would be predicted to
be more likely to have mild and/or intermittent patterns
of pain. The patient population included adult subjects
with recurrent acute pancreatitis (RAP), CP and controls
from the North American Pancreatitis Study 2 (NAPS2).
Methods
Clinical cohort
NAPS2 is the largest prospective molecular epidemiology
and genetics study of RAP and CP in the United States
with recruitment of nearly 1700 subjects from 20 expert
centers [10]. All patients were phenotyped by physicians
with an expertise in pancreatic disease. Additionally, cus-
tom questionnaires that included demographic, environ-
mental, comorbid, phenotypic, quality of life and pain
questions were filled out by both patients and physicians
[10].
The final NAPS2 cohort included 460 subjects with RAP,
540 patients with CP, and 695 healthy controls. Of the
1000 total patients, 540 had completed a pain question-
naire and provided a DNA sample. Eighty-one patients
were excluded because of ambiguous TaqMan® SNP geno-
typing (see methods) results, while an additional 63
patients were excluded because they listed their race as
'African American' or 'Other'. Non-Caucasian populations
are known to have a higher frequency of the uncommon
allele for both SNPs: 50% for SNP1 - rs8007267G>A and
23.8% for SNP2 - rs3783641A>T in our sample, and have
a markedly different pattern of haplotypes, compared to
Caucasians. The final cohort used for analysis included
396 Caucasian patients (265 CP, 131 RAP).
459 healthy controls were identified who were either
spouses of the patients or unrelated individuals without a
history of pancreatic disease or diabetes. Two hundred-
sixty controls were randomly chosen, 16 were excluded
for ambiguous genotyping data, and 8 non-Caucasians
were excluded. The final subgroup used for analysis
included 236 Caucasian controls.
Pain questionnaire
Constant or intermittent episodes of severe pain tend to
be most disruptive to CP patients' lives. The pain ques-
tionnaire for the NAPS2 study was expanded to include
severity by describing 5 pain conditions based on both
pattern (chronicity) and severity (Table 1) [10]. Subjects
were asked to provide the one best answer that describes
the pancreatitis-associated symptoms. The scale allowed
subjects to be categorized by specific pain response, and
by binary analysis for severity (A+B+C {mild} vs. D+E
{severe}) or chronicity (A+C {intermittent} vs. B+D+E
{constant}). For example, a patient with Group 'A' pain
has significantly less pain than a patient with Group 'E'
pain – both in terms of severity and chronicity. Both the
severity and chronicity measures correlate with quality of
life as measured using the Short Form 12 (SF12), (manu-
script in preparation). Fifty-nine subjects (14.9%) were
found to have A pain, 28 (7.1%) B pain, 125 (31.6%) C
pain, 142 (35.9%) D pain, and 41 (10.4%) E pain.Molecular Pain 2008, 4:58 http://www.molecularpain.com/content/4/1/58
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Genotyping
Five SNPs within the Chr14q22.1-q22.2 were used to
define the primary GCH1 "pain-protective haplotype" by
Tegeder et al (see their Figure 6a) [7]. However, the haplo-
type can be defined by 2 SNPs [9]: SNP1 – dbSNP
rs8007267 (c.-9610G>A) and SNP2 – dbSNP rs3783641
(c.343 + 8900A>T) which are located in the promoter
region and intron 1, respectively [9]. These two SNPs were
therefore used to screen for the "pain-protective haplo-
type" in patients with CP.
DNA was extracted and quantified as described by Whit-
comb [10]. Genotypes were determined using TaqMan®
SNP genotyping assays (Applied Biosystems, Foster City,
California, USA). The assays are the same as those
reported in Tegeder et al. Supplementary Table 3 [7].
Thirty-four subjects (28 patients, 6 controls) with unam-
biguous TaqMan® SNP genotyping were sequenced for
SNP 1 and 2 using Big Dye chemistry (Applied Biosys-
tems, Foster City, California, USA) at a 1:4 dilution, but
otherwise according to the manufacturer's directions.
There was 100% concordance between the sequencing
results and those determined by Taqman genotyping for
both common and uncommon alleles. An additional 4
patients were sequenced to resolve ambiguous results
obtained from Taqman genotyping. Resolution of ambig-
uous genotyping results was only performed for Group A,
B, and E patients, for whom there were far fewer subjects
available compared to Group C and D patients. The pri-
mary explanation for ambiguous genotyping results is
attributed to poor DNA quality.
Statistical Analysis
Population haplotype frequencies were estimated by the
expectation-maximization (EM) algorithm and Hidden
Markov Model (HMM) techniques as implemented in
fastPHASE [11]. Comparison of the frequencies of fast-
PHASE-derived haplotype/diplotype configurations in the
case and control groups was examined using Fisher's Exact
Test running under R software http://www.R-project.org.
Differences were considered to be statistically significant
at P < 0.05.
Results
The demographic results for the subjects are presented in
Table 2. Using fastPHASE, the common haplotype (GA),
the uncommon haplotype (AT – also known as the "pain-
protective haplotype"), and other less common haplo-
types were determined. Fisher's exact test for the GA and
AT haplotypes in RAP and CP versus controls was per-
formed and the p-values recorded. Table 3 shows the hap-
lotype frequencies for all patients, CP patients, RAP
patients, healthy controls, as well as the corresponding p-
value. Table 4 shows a subdivision of all patients, CP
patients, and RAP patients into different pain groups. The
only significant finding is the CP patients with group D
pain pattern, who were more likely to possess the uncom-
mon AT haplotype in comparison to controls p = 0.02
(OR = 1.69; CI 1.06–2.68)) which became non-significant
after Bonferroni corrected for multiple testing. Allelic fre-
quencies of the AT haplotype are graphically displayed for
all groups (Figure 1), among different pain groups (Figure
2), and for chronic pancreatitis patients (Figure 3).
Grouping all patients into intermittent pain (A + C) or
constant pain (B + D + E) categories, haplotype frequen-
cies were similar to the control population (p = 0.15 and
0.23, respectively). Similarly, there was no difference
compared to controls for mild pain (A + B + C) or severe
pain (D + E) – (p = 0.14 and 0.21, respectively). Compar-
ison of intermittent vs. constant pain and mild vs. severe
pain were also not significant – p = 0.85 and 0.92, respec-
Table 1: 
Chronic pancreatitis pain questions from the NAPS2 study [10].
 A) I have episodes of mild to moderate pain, usually controlled by the medicines noted above.
 B) I have constant mild to moderate pain, usually controlled by medicines noted above.
 C) I am usually free of abdominal pain, but I have episodes of severe pain.
 D) I have constant mild pain that is controlled (as above), plus episodes of severe pain.
 E) I have constant severe pain that does not change.
Patients in the NAPS2 study were given 5 choices from which to answer the following question. "Several patterns of pain have been described in 
chronic pancreatitis. In this question, please identify the type of pain that best fits your condition"
Table 2: 
Patients Controls
Total 396 236
Males 180 (45.5%) 98 (41.5%)
Females 216 (54.5%) 138 (58.5%)
Age 47.2 +/- 16.1 56.9 +/- 14.8
Chronic pancreatitis 265 (66.9%) 0
Recurrent acute pancreatitis 131 (33.1%) 0
Alcohol associated etiology 134 (33.8%) 0
Other etiologies 262 (66.2%) 0
Smoking history 252 (63.6%) 119 (50.4%)
Demographics of subjects in the patient and control groups.Molecular Pain 2008, 4:58 http://www.molecularpain.com/content/4/1/58
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tively. Separate comparisons of intermittent/continuous
and mild/severe pain for patients with CP and RAP also
did not reach significance (data not shown).
Eleven of 396 (2.7%) subjects with CP or RAP were iden-
tified as being homozygous for "pain-protective haplo-
type" versus 5 of 236 (2.1%) of controls (p = 0.80). There
was no statistically significant variation in the frequency
of patients with a homozygous "pain-protective haplo-
type" among different pain groups (A to E).
Discussion
This is the first study to evaluate the GCH1 "pain protec-
tive" haplotype in a visceral pain syndrome. Unlike neu-
ropathic pain which was persistent in the post-operative
state, there was no association with the "pain protective"
GCH1 haplotype and the individual or combined patient
group (CP and RAP), or individual pain patterns or pain
severity levels in our study. While these findings do not
diminish the importance of the previous findings in post-
surgical sciatica following diskectomy, it does suggest that
the mechanisms of pancreatitis-associated visceral pain
may either be different than in persistent post-surgical sci-
atica, or more heterogeneous.
It is unlikely that the difference between the findings of
Tegeder and the present study are due to differences in
base populations. Indeed, the frequency of the "pain-pro-
tective haplotype" was 17.3% in our patient sample and
15.4% for the patients in the Tegeder study. Similarly, the
control frequencies were also similar, being 14.2% vs.
15.8%, respectively.
The strength of the current study includes the relatively
large sample size and the ability to distinguish various
pain patterns. The limitations include poor understand-
ing of the etiology of the variation in pancreatic pain pat-
terns and severity and limitations in accurate
phenotyping, which is based on the response of patients
to a questionnaire with only 5 categories to describe pain,
administered once during their illness. In contrast, the sci-
atica study reported in Tegeder et al. [7] assessed pain at
three distinct time points, using aggregates scores from
four 7-category scales. The pain measurement literature
suggests that increases in the number of scale categories
above five [12,13] and averaging ratings at 2–7 time
points [14] reduces the error in estimating the magnitude
of chronic pain, or its responses to drug treatment.
Pain is a complex perception that includes both physio-
logic and pathologic components, and involves multiple
pathways and genes. The discovery that GCH1 polymor-
phisms [7], catechol-O-methyltransferase (COMT) poly-
morphisms [15,16], and possibly other "pain gene"
polymorphisms [15] alter perception and tolerance to
pain in humans represent important breakthroughs in
understanding the observed clinical differences in
reported symptoms between patients with similar pathol-
ogies. As noted above, the present study is the first to eval-
uate the GCH1  "pain-protective haplotype" in visceral
pain, but our findings do not rule out the possibility that
GCHI-dependent pathways play an important role in vis-
ceral pain involving other organs, or in small subsets of
pancreatitis-associated pain.
The initial published report of GCH1 genotypes influenc-
ing clinical pain suggested that pain pathways sensitive to
Table 3: 
All pts CP RAP Controls
GA 629 415 214 398
haplotype (79.4) (78.3) (81.7) (84.3)
AT 137 98 39 67
haplotype (17.3) (18.5) (14.9) (14.2)
Other 26 17 9 7
haplotype (3.3) (3.2) (3.4) (1.5)
Fisher 0.11 0.06 0.74 ---
P-value
Haplotype frequency in all subjects formed by rs8007267 and 
rs3783641. Haplotype count with percentage in parentheses. Fisher 
p-value takes into account the GA and AT haplotypes only
Table 4: 
All A All B All C All D All E CP A CP B CP C CP D CP E RAP A RAP B RAP C RAP D RAP E
GA 95 
(80.5)
44 
(81.5)
201 
(79.8)
218 
(76.2)
71 
(86.6)
72 
(81.8)
37 
(80.4)
124 
(77.8)
140 
(74.5)
42 
(87.5)
23 
(76.7)
7 
(87.5)
77 
(83.7)
78 
(80.0)
29 
(85.3)
AT 20 
(17.0)
9 
(16.7)
46 
(18.3)
52 
(18.2)
10 
(12.2)
13 
(14.8)
8 
(17.4)
32 
(20)
40 
(21.3)
5 
(10.4)
7 
(23.3)
1 
(12.5)
14 
(15.2)
12 
(12.2)
5 
(14.7)
Other 3 
(2.5)
1 
(1.9)
5 
(2.0)
16 
(5.6)
1 
(1.2)
3 
(3.4)
1 
(2.2)
4 
(2.5)
8 
(4.3)
1 
(2.1)
0 
(0)
0 
(0)
1 
(1.1)
8 
(8.2)
0 
(0)
Fisher P-value 0.47 0.68 0.16 0.10 0.73 0.87 0.51 0.08 0.02 0.66 0.19 1.0 0.87 0.87 1.0
Haplotype counts among the subject groups subdivided by the subject's response to the pain question (percentage of total haplotype count in 
parentheses). Haplotypes are formed by rs8007267 and rs3783641. AT was reported to be the "pain-protective haplotype" [7]. "All" is CP and RAP 
combined. Fisher's Exact Test compares each category with the haplotype frequencies in the overall control group.Molecular Pain 2008, 4:58 http://www.molecularpain.com/content/4/1/58
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changes in GCH1 expression involve neuropathic pain
[7], which may be uncommon in RAP or CP. GCH1
expression was significantly increased in a rat model of
peripheral neuropathic pain, and blocking GCH1 reduced
the pain response [7]. Additionally, the pain-protective
GCH1 haplotype correlated with decreased persistent leg
pain scores in Caucasian patients who underwent diskec-
tomy, with homozygous genotypes correlating with the
lowest scores and heterozygote genotypes correlating with
intermediate scores [7]. They were also able to replicate
this finding in healthy controls who were exposed to
mechanical pain. Of note, although the GCH1 "pain-pro-
tective haplotype" is associated with reduced neuropathic
pain, the functional SNP(s) have not been defined. 
The above findings have been replicated in other recent
studies. In a study of 10 healthy persons homozygous for
the AT haplotype, the investigators found increased
mechanical pain thresholds if participants were sensitized
with local skin inflammation [17]. In CM Campbell et al.
(under review), pain ratings of 39 healthy subjects admin-
istered topical capsaicin were lower in those with poly-
morphisms in the GCH1 gene. Notably, there was no
association with SNP 1 (rs8007267) [18].
By contrast, Kim et al. [19] analyzed 38 SNPs in the GCH1
gene with a heterozygosity > 0.2 among 221 subjects who
rated pain severity after surgical removal of an impacted
third molar. No association was seen between genetic var-
iations in GCH1 and pain sensitivity. Different findings
among these studies may in part be attributed to varia-
tions in experimental stimuli [20].
Multiple etiologies, and therefore multiple pathways
likely contribute to pancreatic pain [4]. In some cases, the
pattern of pain may provide clues to physiological pain
mechanisms. Intermittent pain, for example, is more
often associated with blockage of the pancreatic duct,
acute pancreatitis, a pseudocyst or other structural lesions
[5]. On the other hand, constant pain is usually associated
with chronic inflammation or an inflammatory mass [5].
Of note, subjects with severe CP pain and long standing
Pain-protective haplotype frequency among subject groups Figure 1
Pain-protective haplotype frequency among subject groups. The frequency of the "pain protective haplotype", given as 
a percent of the total haplotype count. "All patients" includes both CP and RAP. There was no significant difference between 
groups. "Pain protective haplotype" count: All pts = 137, CP = 98, RAP = 39, Controls = 67.Molecular Pain 2008, 4:58 http://www.molecularpain.com/content/4/1/58
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inflammation who subsequently underwent surgery were
found to have an increase in the number of nerves, with
larger cross-sectional areas than seen in the normal pan-
creas [21,22]. The perineural nerve sheath may also
become damaged by infiltrating lymphocytes, causing a
pancreatitis-associated neuritis and neuropathy [23,24].
Additionally, enhanced expression of several neuronal
growth factors have been found to be correlated to the
severity of pain in CP – including growth associated pro-
tein 43, brain derived neurotrophic factor, tyrosine kinase
receptor A (the high affinity receptor for nerve growth fac-
tor), and artemin [24-28]. These lines of evidence suggest
that subjects with CP have inflammation associated pain
rather than neuropathic pain.
In summary, the factors responsible for the marked differ-
ences in pain perception in RAP and CP with similar
pathologies remain unknown. The current study is impor-
tant, however, in that it helps to define pain pathways and
differences in the mechanisms of pain in humans. Taken
together, statistical association of a candidate pain gene
with a specific pain type will help define the pathways
activated in the context of various disorders and injuries,
and may help guide future treatments.
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